非小细胞肺癌分子残留病灶检测的循环肿瘤DNA方法比较
该研究对84例I至III期肺癌患者的417份血浆样本进行头对头比较,评估三种ctDNA-MRD检测策略。个体化肿瘤知情panel在标志时间点的敏感性、特异性及预测值均优于另两种方法,且MRD阳性与更短无病生存期显著相关,纵向监测可提前7.0个月预警复发。
要点
- 个体化肿瘤知情panel检测MRD的敏感性为40.9%,特异性达100.0%。
- 个体化panel检出MRD阳性与显著缩短的无病生存期相关(HR=13.98)。
- 纵向监测中位提前7.0个月预警影像学复发。
核心结论
- 个体化肿瘤知情panel可能优化肺癌术后MRD检测并指导个体化监测。
研究设计与样本
- 头对头比较三种ctDNA-MRD检测策略:肿瘤未知固定panel、肿瘤知情固定panel和肿瘤知情个体化panel。
- 纳入84例I至III期肺癌患者,分析417份血浆样本。
主要发现
- 标志时间点个体化panel敏感性40.9%(p=0.003),特异性100.0%(p<0.001)。
- 个体化panel阴性预测值81.7%(p<0.001),阳性预测值100.0%(p<0.001)。
- 个体化panel检出MRD阳性与更短无病生存期显著相关(p<0.001;HR=13.98;95%CI 1.95-100.37)。
- 纵向MRD监测中位提前7.0个月预警影像学复发。
临床怎么用
- 个体化肿瘤知情panel或可用于肺癌术后MRD检测及复发风险分层。
- 纵向MRD监测有助于提前发现影像学复发,指导术后随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Circulating tumor DNA (ctDNA)-based assays enable the detection of minimal residual disease (MRD) after surgery and are predictive of recurrence in patients with lung cancer. However, the optimal technical strategy remains a subject of active debate. METHODS: We conducted a head-to-head comparison of tumor-naive fixed panel, tumor-informed fixed panel, and tumor-informed personalized panel assays to analyze ctDNA-MRD in 417 plasma samples from 84 patients with stages I to III lung cancer. RESULTS: At the landmark time point, the personalized assay achieved superior performance compared with the tumor-naive and tumor-informed assays, with a sensitivity of 40.9% (p = 0.003), a specificity of 100.0% (p < 0.001), a negative predictive value of 81.7% (p < 0.001), and a positive predictive value of 100.0% (p < 0.001). MRD positivity by the personalized assay was associated with significantly shorter disease-free survival (p < 0.001; hazard ratio = 13.98; 95% confidence interval: 1.95-100.37). Longitudinal MRD monitoring using the personalized assay improved relapse prediction, providing a median lead time of 7.0 months before radiologic recurrence. CONCLUSION: The personalized assays may optimize MRD detection and inform individualized postoperative surveillance in lung cancer.
引用
- Cui Q, Zhang JT, Yin H, et al. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in NSCLC. J Thorac Oncol. 2026. PMID: 42448176. doi:10.1016/j.jtho.2026.104090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。